**Caspofungin**

| Spectrum of Activity* | *Candida,* including fluconazole resistant species: *C. glabrata* and *C. krusei*  
Aspergillus |
|-----------------------|---------------------------------------------------------------|
| **Indications**       | Primary indication(s): empiric antifungal for severely ill  
patients with invasive *Candida* infection or patients at risk of  
fluconazole resistance (e.g. receiving fluconazole  
prophylaxis). Empiric yeast therapy for febrile neutropenia.  
Fungal endocarditis  
Alternative: An option for invasive aspergillosis infections, but  
amphotericin or voriconazole is usually preferred. |
| **Not indicated**     | The echinocandins have poor urine penetration and should  
generally not be used for urinary infections.  
Should not be used for CNS infections. |
| **Safety Considerations** | Reduce dose if moderate hepatic impairment (Child Pugh B) |
| **Renal Dosing**      | No adjustments required for renal impairment |
| **Other Considerations** | Higher dose is required for fungal endocarditis (150mg/day) |